What do systematic reviews say?

Postoperative MMC‐EMDA induction vs postoperative BCG induction therapy

It is very uncertain whether postoperative MMC‐EMDA induction changes time to recurrence compared with postoperative BCG induction therapy (very low certainty).

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  RR 1.06 [0.64, 1.76]
  1 study · 72 participants
  Very low

Postoperative MMC‐EMDA induction vs postoperative BCG induction therapy

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 72 participants
  Low

Postoperative MMC‐EMDA induction vs postoperative BCG induction therapy

It is very uncertain whether postoperative MMC‐EMDA induction changes serious adverse events compared with postoperative BCG induction therapy (very low certainty).

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  RR 0.75 [0.18, 3.11]
  1 study · 72 participants
  Very low

Postoperative MMC‐EMDA induction vs postoperative BCG induction therapy

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 72 participants
  Low

Postoperative MMC‐EMDA induction vs postoperative BCG induction therapy

The review found no eligible studies for this question.

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Postoperative MMC‐EMDA induction vs MMC‐PD induction therapy

The review found no eligible studies for this question.

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Postoperative MMC‐EMDA induction vs MMC‐PD induction therapy

Postoperative MMC‐EMDA induction may leads to lower time to recurrence compared with MMC‐PD induction therapy (low certainty).

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  RR 0.65 [0.44, 0.98]
  1 study · 72 participants
  Low

Postoperative MMC‐EMDA induction vs MMC‐PD induction therapy

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 72 participants
  Low

Postoperative MMC‐EMDA induction vs MMC‐PD induction therapy

It is very uncertain whether postoperative MMC‐EMDA induction changes serious adverse events compared with MMC‐PD induction therapy (very low certainty).

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  RR 1.5 [0.27, 8.45]
  1 study · 72 participants
  Very low

Postoperative MMC‐EMDA induction vs MMC‐PD induction therapy

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 72 participants
  Low

Postoperative MMC‐EMDA with sequential BCG induction and maintenance vs postoperative BCG induction and maintenance therapy

Postoperative MMC‐EMDA with sequential BCG induction and maintenance may leads to lower time to recurrence compared with postoperative BCG induction and maintenance therapy (low certainty).

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  HR 0.51 [0.34, 0.77]
  1 study · 212 participants
  Low

Postoperative MMC‐EMDA with sequential BCG induction and maintenance vs postoperative BCG induction and maintenance therapy

Postoperative MMC‐EMDA with sequential BCG induction and maintenance may leads to lower time to progression compared with postoperative BCG induction and maintenance therapy (low certainty).

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  HR 0.36 [0.17, 0.75]
  1 study · 212 participants
  Low

Postoperative MMC‐EMDA with sequential BCG induction and maintenance vs postoperative BCG induction and maintenance therapy

It is very uncertain whether postoperative MMC‐EMDA with sequential BCG induction and maintenance changes serious adverse events compared with postoperative BCG induction and maintenance therapy (very low certainty).

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  RR 1.02 [0.21, 4.94]
  1 study · 212 participants
  Very low

Postoperative MMC‐EMDA with sequential BCG induction and maintenance vs postoperative BCG induction and maintenance therapy

Postoperative MMC‐EMDA with sequential BCG induction and maintenance may leads to lower disease‐specific survival compared with postoperative BCG induction and maintenance therapy (low certainty).

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  HR 0.31 [0.12, 0.8]
  1 study · 212 participants
  Low

Postoperative MMC‐EMDA with sequential BCG induction and maintenance vs postoperative BCG induction and maintenance therapy

The review found no eligible studies for this question.

• Intravesical electromotive drug administration for non‐muscle invasive bladder cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found